Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX:...
Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024
Seaking AlphaSeeking Alpha / Seaking Alpha 17 hours ago 1 Views
Comments